Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that PGF2alpha analogues and PGE2 stimulated hair follicle activity in mice, with PGF2alpha analogues also linked to potential side effects like poliosis when used as eye treatments.

This study at Gajra Raja Medical College found that topical methotrexate with tretinoin was more effective but not significantly better than betamethasone with tretinoin for treating alopecia areata over six months, with similar safety profiles between the treatments.

This study found that while the combination of oral propranolol and intradermal injections in guinea pigs led to psoriasiform changes, it did not fully mimic psoriasis.

In this case report, a 47-year-old man with extensive psoriasis saw significant improvement in scaling and itching after using a new lotion containing clobetasol and other ingredients for one week, but further research is needed to confirm these findings.

This study reports a case of a 59-year-old female with refractory follicular mucinosis and diffuse scalp alopecia who achieved complete clinical remission following treatment with a combination of topical tacalcitol and photodynamic therapy.

This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.

This study reported that therapeutic make-up significantly improves the long-term quality of life for patients with facial dermatoses, showing a sustained benefit one year after application, particularly in younger patients.

Topical imiquimod is as effective as 5-fluorouracil for treating actinic keratosis, with about a 5% risk of it turning into squamous cell carcinoma.

This article highlights the benefits of combining calcipotriene and betamethasone for treating localized plaque-type, scalp, and nail psoriasis, enhancing effectiveness while reducing side effects compared to single-agent therapies.

This case report describes two instances of hyper-pigmentation induced by prolonged misuse of Betnovate cream, where cessation and appropriate treatment led to significant improvement within 15 days.

This review reports no new results and discusses various topical treatments, noting that fluocortin butyl ester offers anti-inflammatory effects without systemic side effects, while combinations outperform single-agent therapies in managing hyperpigmentation.

This study found that applying 5% topical minoxidil gel on treatment-resistant vitiligo patches may promote early repigmentation, showing significant improvement at one month compared to a placebo, though later differences were not statistically significant.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

This study found that calcitriol, tacalcitol, and calcipotriol ointments achieved complete clearance of scalp psoriasis in 45%, 35.2%, and 17.6% of patients, respectively, with minimal side effects.

This study found that compounded topical minoxidil was associated with higher adherence, fewer side effects, and more clinical improvement in Black women compared to over-the-counter minoxidil.

In this randomized controlled trial, PRP combined with redensyl, saw palmetto, and biotin showed superior efficacy in improving androgenetic alopecia grading scores in male patients when compared to PRP with Procapil.

This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.

This review discusses the potential applications of prostaglandin F2α analogs for certain types of alopecia and hypopigmentation, but reports no new experimental results.

This case report highlights a rare side effect of prostaglandin analogues, detailing prostaglandin-associated periorbitopathy in three glaucoma patients treated with bimatoprost and travoprost.

This study found that combining microneedling with clobetasol propionate 0.05% cream significantly improved complete hair regrowth in alopecia areata patches compared to using the cream alone, with nearly double the rate of full hair regrowth observed in the combination treatment group.

In this study, a novel topical bimatoprost formulation (BIM-TF#5) significantly enhanced hair regrowth and increased dermal drug deposition in both human skin models and an androgenic alopecia mouse model compared to previous preparations.

This source reports that bimatoprost, a medication approved for eyelash growth, has shown efficacy in treating eyebrow hypotrichosis, suggesting it as a noninvasive, effective, and well-tolerated option for enhancing eyebrow hair.

This review summarizes therapeutic advances reported in English-language literature from December 1987 to December 1988 and states no new clinical results.

Some moles can disappear naturally, maintenance therapy for Stage 1 mycosis fungoides may not be necessary, allergic skin reactions in children are rising, weekly methotrexate for psoriasis is more effective than daily, long-term finasteride use improves hair growth with few side effects, and petrolatum improves UV therapy for psoriasis.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

This study found that proretinal nanoparticles, applied topically, are safe and effective for penetration into hair follicles, enhancing retinoid biological activity in the skin while reducing irritation compared to conventional retinal formulations.

Topical minoxidil showed promise for early male pattern baldness.

In this study, bimatoprost 0.03% was effective and well-tolerated for improving eyelash hypotrichosis in healthy adolescents, but not for those with the condition due to chemotherapy or alopecia areata.

This study found that using a method based on absolute PASI, patients with psoriasis receiving brodalumab had a higher probability of achieving and maintaining a treatment response over 52 weeks compared to those receiving ustekinumab.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.